Impact BioMedical Inc Dossier - Source-backed chat

Impact BioMedical Inc

IBONYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.13

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.43Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $46.4M

Enterprise Value $46.4M

Shares Outstanding 107.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Impact BioMedical Inc. (NYSE American: IBO) is a development-stage biotechnology platform focused on specialty biopharmaceuticals and consumer healthcare. The company is currently pre-revenue, generating only $32,000 in retail sales from its newly acquired Celios air purification technology in 2025, while posting a net loss of $11.87 million. Its financial position is highly constrained, leading to a 'going concern' qualification in its 2025 Form 10-K. However, the company has significantly de-risked its balance sheet by converting approximately $15 million of DSS debt into common shares, eliminating all non-trade debt. The primary catalyst for the company is its pending strategic reverse merger with Dr. Ashleys Limited, which has been extended to July 1, 2026. This merger will combine Dr. Ashleys' global pharmaceutical manufacturing capabilities with Impact's extensive patent portfolio (69 issued and over 60 pending patents) into a single NYSE American-traded entity. Given the high execution risks and pre-revenue status, a Hold recommendation is advised until the merger is finalized and commercial synergies begin to materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger with Dr. Ashleys Limited faces further delays or fails to close, leaving Impact BioMedical with less than a year of cash runway and no viable path to commercialization. The company is forced to execute highly dilutive equity raises or faces potential delisting from the NYSE American due to its going concern status and negative equity.

Base CaseCentral scenario

The strategic reverse merger with Dr. Ashleys Limited closes successfully by the extended deadline of July 1, 2026. The combined entity leverages Dr. Ashleys' manufacturing footprint to begin commercializing Impact's patented technologies (such as Laetose, Linebacker, and 3F), gradually generating meaningful revenue and resolving the going concern uncertainty.

Bull CaseUpside scenario

The bull case for Impact BioMedical centers on its pending strategic reverse merger with global pharmaceutical company Dr. Ashleys Limited (projected to close around July 1, 2026, to form a combined public entity on the NYSE American). This transaction is expected to provide the global reach, manufacturing capabilities, and financial resources necessary to commercialize Impact's patented healthcare and wellness technology platforms, which include Linebacker (oncology/neurology), Laetose (sugar alternative), 3F (botanical insect repellent/antimicrobial), and Equivir (antiviral).

Scenarios reflect our research view at the research date.

Key Investment Merits

Extensive intellectual property portfolio with 69 issued patents and over 60 pending patents worldwide.
Elimination of all non-trade debt through the conversion of $15 million in DSS debt into common shares.
Pending reverse merger with Dr. Ashleys Limited provides a direct path to global pharmaceutical manufacturing and commercialization.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
Pre-revenue operational status with only $32,000 in retail sales against an $11.87 million net loss in 2025.
High historical share price volatility and substantial shareholder dilution over the past year.

Thesis Invalidation Triggers

Termination or failure to close the merger with Dr. Ashleys Limited by July 1, 2026.
Inability to secure additional financing or joint venture partnerships to fund ongoing operations.
Delisting notification from the NYSE American exchange.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.